University of Missouri announces initiative for NextGen MURR, a new research reactor to improve and save lives through advanced nuclear medicines
Request for Qualification/Request for Proposal is the first step for NextGen MURR as MU looks to expand its capabilities in medical radioisotope development.
Copper artifacts unearth new cultural connections in southern Africa
A University of Missouri researcher and colleagues use geochemical analyses on copper objects to reveal centuries of previously unknown connections within the region.
Radioligand therapy, a ‘game-changer’ for cancer treatment
Radioligand therapy is featured on CNBC.com
A smoky solution — for plants
After MU researchers started examining the impact of smoke on plant growth after a wildfire, their surprising discovery could one day lead to new farming practices.
At the forefront of nuclear medicine
For decades, MU has been a leader in developing lifesaving cancer treatments and is now set to play an integral role in an ongoing radiopharmaceutical renaissance.
A chance at ‘upcycling’ life
A mid-Missouri woman benefits from the power of advancements in science and medicine harnessed at the University of Missouri.
New domestic supply chain: Gold-199
MURR is now producing Au-199 in partnership with the Department of Energy Isotope Program.
University of Missouri Board of Curators approves capital projects
The University of Missouri Research Reactor (MURR) will get an approximately 40,000-square-foot addition to expand the existing facility with an estimated completion date in fall 2024.
MU research reactor helps supply critical medical isotopes during global disruption
Due to a recent unexpected reactor shutdown in Europe, the University of Missouri Research Reactor (MURR) has increased its production of critical medical radioisotopes in an effort to help alleviate the anticipated disruption on the global supply chain.
ABK Biomedical Announces Enrollment Initiation of First-in-Human Clinical Study with Eye90 microspheres™ for treatment of liver tumors
ABK Biomedical, Inc., a MURR partner, has announced the initiation of a First-in-Human study with their Eye90 microspheres™